End-of-day quote
OTC Markets
06:00:00 2021-08-31 pm EDT
|
5-day change
|
1st Jan Change
|
2.63
CAD
|
-6.07%
|
|
+17.41%
|
+76.51%
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
205.5
|
177.2
|
102.4
|
425.4
|
331.2
|
-
|
-
|
Enterprise Value (EV)
1 |
141.4
|
123.5
|
85.8
|
216.7
|
189.8
|
269.1
|
210.6
|
P/E ratio
|
-4.1
x
|
-2.55
x
|
-2
x
|
-2.24
x
|
-4.84
x
|
-3.63
x
|
-4.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
238
x
|
-
|
-
|
-
|
-
|
-
|
2.82
x
|
EV / Revenue
|
164
x
|
-
|
-
|
-
|
-
|
-
|
1.79
x
|
EV / EBITDA
|
-7.38
x
|
-2.71
x
|
-1.84
x
|
-2.76
x
|
-2.26
x
|
-3.18
x
|
-3.16
x
|
EV / FCF
|
-7.38
x
|
-2.73
x
|
-1.8
x
|
-3.14
x
|
-2.92
x
|
-3.19
x
|
-25.8
x
|
FCF Yield
|
-13.5%
|
-36.7%
|
-55.4%
|
-31.8%
|
-34.2%
|
-31.3%
|
-3.88%
|
Price to Book
|
1.52
x
|
2.24
x
|
2
x
|
0.6
x
|
1.61
x
|
2.56
x
|
1.89
x
|
Nbr of stocks (in thousands)
|
156,782
|
173,458
|
196,913
|
760,053
|
760,053
|
-
|
-
|
Reference price
2 |
1.310
|
1.021
|
0.5202
|
0.5597
|
0.4357
|
0.4357
|
0.4357
|
Announcement Date
|
6/28/21
|
6/22/22
|
6/27/23
|
6/26/24
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
-
|
0.864
|
-
|
-
|
-
|
-
|
-
|
117.4
|
EBITDA
1 |
-
|
-19.17
|
-45.64
|
-46.58
|
-78.41
|
-84
|
-84.55
|
-66.6
|
EBIT
1 |
-
|
-32.28
|
-63.84
|
-51.52
|
-78.84
|
-76.99
|
-93.38
|
-4.003
|
Operating Margin
|
-
|
-3,736.11%
|
-
|
-
|
-
|
-
|
-
|
-3.41%
|
Earnings before Tax (EBT)
1 |
-
|
-32.22
|
-67.63
|
-47.49
|
-78.08
|
-77.13
|
-89.13
|
-78.38
|
Net income
1 |
-0.8098
|
-32.22
|
-67.63
|
-47.49
|
-78.08
|
-77.13
|
-92.98
|
-26.77
|
Net margin
|
-
|
-3,729.17%
|
-
|
-
|
-
|
-
|
-
|
-22.81%
|
EPS
2 |
-
|
-0.3200
|
-0.4000
|
-0.2600
|
-0.2500
|
-0.0900
|
-0.1200
|
-0.0967
|
Free Cash Flow
1 |
-
|
-19.16
|
-45.31
|
-47.57
|
-68.93
|
-64.89
|
-84.31
|
-8.16
|
FCF margin
|
-
|
-2,217.82%
|
-
|
-
|
-
|
-
|
-
|
-6.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/20
|
6/28/21
|
6/22/22
|
6/27/23
|
6/26/24
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-11.95
|
-12.95
|
-11.19
|
-11.2
|
-11.04
|
-13.15
|
-12.64
|
-13.84
|
-26.88
|
-25.05
|
-17.8
|
-17.8
|
-24.3
|
-24.3
|
EBIT
1 |
-16.46
|
-16.34
|
-13.4
|
-12.33
|
-12.09
|
-13.7
|
-12.71
|
-13.91
|
-27.02
|
-25.2
|
-18
|
-18
|
-24.5
|
-24.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.21
|
-18.1
|
-13.06
|
-9.973
|
-10.74
|
-13.72
|
-14.51
|
-11.89
|
-30.33
|
-21.35
|
-16.2
|
-16.3
|
-23
|
-23.1
|
Net income
1 |
-17.21
|
-18.1
|
-13.06
|
-10
|
-10.74
|
-13.72
|
-14.51
|
-11.89
|
-30.33
|
-21.35
|
-16.2
|
-16.3
|
-23
|
-23.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1000
|
-0.1000
|
-0.0700
|
-0.0600
|
-0.0600
|
-0.0700
|
-0.0700
|
-0.0500
|
-0.0900
|
-0.0200
|
-0.0200
|
-0.0200
|
-0.0300
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
6/22/22
|
8/8/22
|
11/14/22
|
2/14/23
|
6/27/23
|
8/14/23
|
11/14/23
|
2/14/24
|
6/26/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
64
|
53.6
|
16.6
|
209
|
141
|
62.1
|
121
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-19.2
|
-45.3
|
-47.6
|
-68.9
|
-64.9
|
-84.3
|
-8.16
|
ROE (net income / shareholders' equity)
|
-
|
-73.6%
|
-79.2%
|
-76.4%
|
-45.9%
|
-30.4%
|
-52.3%
|
-58.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.8600
|
0.4600
|
0.2600
|
0.9300
|
0.2700
|
0.1700
|
0.2300
|
Cash Flow per Share
2 |
-
|
-0.1900
|
-0.2700
|
-0.2600
|
-0.2200
|
-0.0800
|
-0.0900
|
-0.0900
|
Capex
1 |
-
|
0.14
|
0.11
|
0.14
|
0.02
|
3.01
|
5.89
|
8.78
|
Capex / Sales
|
-
|
15.62%
|
-
|
-
|
-
|
-
|
-
|
7.48%
|
Announcement Date
|
11/9/20
|
6/28/21
|
6/22/22
|
6/27/23
|
6/26/24
|
-
|
-
|
-
|
Last Close Price
0.4357
CAD Average target price
5.86
CAD Spread / Average Target +1,244.98% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.12% | 126B | | +25.25% | 119B | | +25.56% | 27.95B | | -19.51% | 20.5B | | -14.36% | 17.12B | | -15.63% | 16.1B | | -46.67% | 14.97B | | +11.89% | 14.84B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|